20/20 Biolabs, Inc. Common Stock (AIDX) is a publicly traded the market company. As of May 21, 2026, AIDX trades at $1.30 with a market cap of $13.83M and a P/E ratio of 0.00. AIDX moved +0.00% today. Year to date, AIDX is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $1.26 to $50.00. Analyst consensus is strong buy with an average price target of $2.76. Rallies surfaces AIDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
20/20 BioLabs Posts $4.2M Cash, $0.4M Q1 Revenue; Evexia and ROKIT Deals: 20/20 BioLabs reported Q1 revenue of $0.4M, down from $0.6M year-over-year, and ended March with $4.2M cash after a $5M private placement. State firefighter programs, Evexia distribution and ROKIT CKD license support OneTest™ expansion and 2026 revenue growth ahead of Medicare MCED reimbursement in 2028.
| Metric | Value |
|---|---|
| Price | $1.30 |
| Market Cap | $13.83M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $50.00 |
| 52-Week Low | $1.26 |
| Volume | 36.56K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover AIDX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $2.76.